Security
Ernexa Therapeutics Inc. Common Stock · ERNA
ERNANASDAQCommon stockHistorical · closed Oct 19, 2026CIK 748592Updated Nov 2, 2026
Name history
Eterna Therapeutics Inc. · through Apr 4, 2025Brooklyn ImmunoTherapeutics, Inc. · through Oct 14, 2022NTN BUZZTIME INC · through Mar 23, 2021NTN COMMUNICATIONS INC · through Dec 20, 2005
Current security for this SEC filerERNA · NASDAQ
ERNA price & chart
Historical security
This listing closed Oct 19, 2026. Live provider charts are shown only for current listings.
Current security: ERNA
About the company
We are a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are induced pluripotent stem cell (“iPSC”)-derived mesenchymal stem cells. We envision a future where cell therapies powered by synthetic iMSCs can offer new options for patients with limited treatment paths and our mission is to transform the treatment of cancer and autoimmune disease by developing scalable, affordable, off-the-shelf cell therapies that restore hope.
In the news
Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer News provided by Cellipont Bioservices Oct 29, 2025, 10:33 ET Share this article Share to X Share this article Share to X THE WOODLANDS, Texas, and ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
SCHEDULE 13G/A - filed by CLEAR STREET LLC regarding Ernexa Therapeutics Inc.
SCHEDULE 13G/A - filed by Freebird Partners LP regarding Ernexa Therapeutics Inc.
SCHEDULE 13G/A - filed by HALPERN JOHN D regarding Ernexa Therapeutics Inc.
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 6,172,000Source | 7,718,000Source | 6,315,000Source | 7,584,000Source | 46,486,000Source | 10,543,000Source | 5,059,000Source | 49,657,000Source | 5,834,000Source | 5,269,000Source | 49,132,000Source | 22,279,000Source |
| Property, Plant and Equipment, NetUSD | 92,000Source | 105,000Source | 82,000Source | 50,000Source | 654,000Source | 88,000Source | 67,000Source | 710,000Source | 94,000Source | 85,000Source | 493,000Source | 236,000Source |
| GoodwillUSD | 2,044,000Source | 2,044,000Source | — | 2,044,000Source | 2,044,000Source | — | 2,044,000Source | 2,044,000Source | 2,044,000Source | 2,044,000Source | 2,044,000Source | 2,044,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 4,264,000Source | — | 4,315,000Source | 2,586,000Source | — | 1,918,000Source | 5,116,000Source | — | 1,729,000Source | 7,575,000Source | 11,446,000Source |
| Assets, CurrentUSD | 3,379,000Source | 4,730,000Source | 5,894,000Source | 4,792,000Source | 3,583,000Source | 9,996,000Source | 2,211,000Source | 6,164,000Source | 3,133,000Source | 2,352,000Source | 9,599,000Source | 13,681,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 179,000Source | 279,000Source | 783,000Source | 323,000Source | 769,000Source | 724,000Source | 137,000Source | 697,000Source | 404,000Source | 186,000Source | 1,599,000Source | 1,284,000Source |
| Operating Lease, Right-of-Use AssetUSD | 541,000Source | 719,000Source | 314,000Source | 581,000Source | 35,990,000Source | 349,000Source | 619,000Source | 36,524,000Source | 453,000Source | 670,000Source | 32,781,000Source | 1,030,000Source |
| Other Assets, NoncurrentUSD | 116,000Source | 120,000Source | 25,000Source | 117,000Source | 120,000Source | 110,000Source | 118,000Source | 120,000Source | 110,000Source | 118,000Source | 120,000Source | 1,134,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,602,000Source | 53,111,000Source | 3,115,000Source | 3,140,000Source | 55,012,000Source | 3,684,000Source | 11,009,000Source | 53,069,000Source | 3,433,000Source | 3,568,000Source | 46,899,000Source | 10,172,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | — | 1,000Source | 1,000Source | — | — |
| Common Stock, Value, IssuedUSD | 39,000Source | 27,000Source | 6,000Source | 37,000Source | 27,000Source | 6,000Source | 262,000Source | 27,000Source | 39,000Source | 257,000Source | 27,000Source | 26,000Source |
| Additional Paid in CapitalUSD | 247,656,000Source | 600,000Source | 258,352,000Source | 247,291,000Source | 190,611,000Source | 257,994,000Source | 233,525,000Source | 190,188,000Source | 247,997,000Source | 232,979,000Source | 189,186,000Source | 177,377,000Source |
| Retained Earnings (Accumulated Deficit)USD | -244,126,000Source | -225,769,000Source | -255,159,000Source | -242,885,000Source | -199,165,000Source | -251,142,000Source | -239,738,000Source | -193,628,000Source | -245,636,000Source | -231,536,000Source | -186,981,000Source | -165,297,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,570,000Source | -45,393,000Source | 3,200,000Source | 4,444,000Source | -8,526,000Source | 6,859,000Source | -5,950,000Source | -3,412,000Source | 2,401,000Source | 1,701,000Source | 2,233,000Source | 12,107,000Source |
| Liabilities and EquityUSD | 6,172,000Source | 7,718,000Source | 6,315,000Source | 7,584,000Source | 46,486,000Source | 10,543,000Source | 5,059,000Source | 49,657,000Source | 5,834,000Source | 5,269,000Source | 49,132,000Source | 22,279,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,144,000Source | 9,952,000Source | 2,932,000Source | 2,651,000Source | 9,600,000Source | 3,457,000Source | 10,438,000Source | 7,768,000Source | 3,113,000Source | 2,938,000Source | 6,573,000Source | 7,654,000Source |
| Operating Lease, Liability, CurrentUSD | 206,000Source | 201,000Source | 167,000Source | 217,000Source | 4,266,000Source | 163,000Source | 213,000Source | 2,874,000Source | 213,000Source | 207,000Source | 2,216,000Source | 295,000Source |
| Accounts Payable, CurrentUSD | 958,000Source | 2,193,000Source | 1,375,000Source | 1,319,000Source | 2,193,000Source | 1,300,000Source | 1,275,000Source | 2,063,000Source | 1,125,000Source | 1,721,000Source | 1,067,000Source | 1,620,000Source |
| Operating Lease, Liability, NoncurrentUSD | 346,000Source | 534,000Source | 182,000Source | 376,000Source | 36,044,000Source | 226,000Source | 419,000Source | 36,565,000Source | 277,000Source | 477,000Source | 32,854,000Source | 887,000Source |
| Other Liabilities, NoncurrentUSD | 112,000Source | 84,000Source | 1,000Source | 113,000Source | 84,000Source | 1,000Source | 111,000Source | 84,000Source | 43,000Source | 111,000Source | — | 94,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 859,000Source | 1,166,000Source | 1,016,000Source | 938,000Source | 2,389,000Source | 1,481,000Source | 1,354,000Source | 1,868,000Source | 898,000Source | 1,007,000Source | 1,893,000Source | 3,626,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | — | 189,000Source | — | — | 189,000Source | — | — | 190,000Source | — |
| Deferred Revenue, NoncurrentUSD | — | — | — | — | 298,000Source | — | — | 345,000Source | — | — | 392,000Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 41,000Source | 88,000Source | 60,000Source | 65,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 8,000Source | 18,000Source | 65,000Source | 139,000Source | 84,000Source | 161,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 309,000Source | 502,000Source | 1,496,000Source | 1,520,000Source | 1,242,000Source | 2,935,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -48,000Source | 27,000Source | -2,149,000Source | -8,640,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,264,000Source | -2,065,000Source | -7,017,000Source | -15,836,000Source | -20,408,000Source | -20,976,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -2,000Source | — | -37,000Source | -365,000Source | -19,000Source | -47,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 2,000Source | — | 37,000Source | 369,000Source | 19,000Source | 297,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 5,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 9,559,000Source | 2,254,000Source | 7,209,000Source | 6,260,000Source | 16,556,000Source | 19,579,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 3,047,000Source | 4,264,000Source | 5,028,000Source | 4,315,000Source | 9,177,000Source | 1,918,000Source | 1,884,000Source | 1,729,000Source | 11,670,000Source | 15,541,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 6,000Source | 48,000Source | 20,000Source | 30,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 3,000Source | 2,000Source | 4,000Source | 15,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 293,000Source | 405,000Source | 320,000Source | 368,000Source | 308,000Source | 502,000Source | 1,496,000Source | 1,520,000Source | 1,242,000Source | 2,935,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | 5,259,000Source | 303,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | 100,000Source | 100,000Source | 100,000Source | 161,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | — | -11,000Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | — | — | — | — | — | -13,000Source | — | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | 1,576,000Source | — | — | 56,000Source | — | — | 1,576,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 734,000Source | -22,440,000Source | 41,000Source | -500,000Source | — | -5,300,000Source | 765,000Source | -22,440,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 958,000Source | 3,381,000Source | 1,312,000Source | 1,365,000Source | 1,631,000Source | 1,421,000Source | 5,163,000Source | 13,132,000Source | 14,587,000Source | 16,835,000Source |
| GoodwillUSD | — | — | 2,044,000Source | 2,044,000Source | — | 2,044,000Source | — | 2,044,000Source | 2,044,000Source | 2,044,000Source | 2,044,000Source | 2,044,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 2,044,000Source | — | — | — | 0Source | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 33,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 6,000Source | 12,000Source | — | 3,000Source | -40,000Source | 8,000Source | -45,000Source | 30,000Source | -3,000Source | 45,000Source |
| InterestExpenseNonoperatingUSD | — | — | — | 1,700,000Source | — | — | — | 800,000Source | -100,000Source | 6,500,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,240,000Source | -26,604,000Source | -4,009,000Source | -3,139,000Source | -5,506,000Source | -8,202,000Source | -14,084,000Source | -44,539,000Source | -21,668,000Source | -24,579,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -1,240,000Source | -26,604,000Source | -4,017,000Source | -3,147,000Source | — | — | -14,100,000Source | -44,555,000Source | -21,684,000Source | -24,595,000Source |
| Noncash Merger Related CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Nonoperating Income (Expense)USD | — | — | 759,000Source | -24,333,000Source | 95,000Source | -635,000Source | 44,000Source | -5,464,000Source | -4,810,000Source | -28,835,000Source | -536,000Source | 8,683,000Source |
| Operating ExpensesUSD | — | — | 1,993,000Source | 2,806,000Source | 4,104,000Source | 2,501,000Source | 5,590,000Source | 2,730,000Source | 9,319,000Source | 16,160,000Source | 20,967,000Source | 33,217,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 33,000Source | — | 0Source | 772,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -6,000Source | — | -1,000Source | -123,000Source | — | -135,000Source | 215,000Source | 70,000Source | -334,000Source | -1,171,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 10,480,000Source | — | 4,929,000Source | 1,137,000Source | 0Source | 19,706,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 487,000Source | — | — | — | — | — | 582,000Source | 68,000Source | — |
| Cost of Goods and Services Sold | — | — | — | —Source | —Source | —Source | — | — | — | —Source | —Source | — |
| Operating Income (Loss)USD | — | — | -1,993,000Source | -2,259,000Source | -4,104,000Source | -2,501,000Source | -5,590,000Source | -2,730,000Source | -9,319,000Source | -15,674,000Source | -21,135,000Source | -33,217,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -6,000Source | — | -1,000Source | -123,000Source | — | -135,000Source | 215,000Source | 70,000Source | -334,000Source | -1,171,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -1,234,000Source | -26,592,000Source | -4,009,000Source | -3,136,000Source | -5,546,000Source | -8,194,000Source | -14,129,000Source | -44,509,000Source | -21,671,000Source | -24,534,000Source |
| Income Tax Expense (Benefit)USD | — | — | 6,000Source | 12,000Source | — | 3,000Source | -40,000Source | 8,000Source | -45,000Source | 30,000Source | -3,000Source | 45,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,240,000Source | -26,604,000Source | -4,009,000Source | -3,139,000Source | -5,506,000Source | -8,202,000Source | -14,084,000Source | -44,539,000Source | -21,668,000Source | -24,579,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.15Source | -73.7Source | -3.4Source | -15.19Source | -6.95Source | -57.76Source | -2.24Source | -3.26Source | -4.08Source | -8.06Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.15Source | -73.7Source | -3.4Source | -15.19Source | -6.95Source | -57.76Source | -2.24Source | -3.26Source | -4.08Source | -8.06Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 8,226,000Source | 361,000Source | 1,183,000Source | 207,000Source | 792,000Source | 142,000Source | 6,307,000Source | 13,647,000Source | 5,314,000Source | 3,051,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 8,226,000Source | 361,000Source | 1,183,000Source | 207,000Source | 792,000Source | 142,000Source | 6,307,000Source | 13,647,000Source | 5,314,000Source | 3,051,000Source |
| Interest Expense (non-operating)USD | — | — | — | 1,700,000Source | — | — | — | 800,000Source | -100,000Source | 6,500,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Cost of Property Repairs and MaintenanceUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 3,000Source | 3,000Source | 1,000Source | 4,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 100,000Source | 100,000Source | 100,000Source | 500,000Source | 9,000Source | 18,000Source | 100,000Source | 100,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 958,000Source | 3,381,000Source | 1,312,000Source | 1,365,000Source | 1,631,000Source | 1,421,000Source | 5,163,000Source | 13,132,000Source | 14,587,000Source | 16,835,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 2,044,000Source | — | — | — | 0Source | — |
| Gross ProfitUSD | — | — | — | 547,000Source | — | — | — | — | — | 486,000Source | -168,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -14,129,000Source | -44,529,000Source | -21,654,000Source | -24,513,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 614,000Source | — |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | 6,000Source | 22,000Source | 174,000Source | 176,000Source | — |
| InterestExpenseOperatingUSD | — | — | — | — | — | — | — | — | — | 1,400,000Source | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 31,000Source | -1,686,000Source | 55,000Source | — | 44,000Source | 5,000Source | -27,000Source | -6,752,000Source | — | — |
| Interest Income, OtherUSD | — | — | — | — | 55,000Source | — | 44,000Source | 5,000Source | 100,000Source | — | — | — |
| Investment Income, NetUSD | — | — | — | — | — | — | — | — | 83,000Source | 249,000Source | 138,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -1,240,000Source | -26,604,000Source | -4,017,000Source | -3,147,000Source | — | — | -14,100,000Source | -44,555,000Source | -21,684,000Source | -24,595,000Source |
| Nonoperating Income (Expense)USD | — | — | 759,000Source | -24,333,000Source | 95,000Source | -635,000Source | 44,000Source | -5,464,000Source | -4,810,000Source | -28,835,000Source | -536,000Source | 8,683,000Source |
| Operating ExpensesUSD | — | — | 1,993,000Source | 2,806,000Source | 4,104,000Source | 2,501,000Source | 5,590,000Source | 2,730,000Source | 9,319,000Source | 16,160,000Source | 20,967,000Source | 33,217,000Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | 100,000Source | — | — |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | — | 8,000Source | 8,000Source | — | — | 16,000Source | 16,000Source | 16,000Source | 16,000Source |
Offerings
Registration 333-294307
Registration 333-293150
Filing attachments
ex99-1.htm · SCHEDULE 13G · 2026-05-14
Exhibit 99.1 AGREEMENT OF THE REPORTING PERSONS The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and ac…
Read attachment ↗ex99-2.htm · SCHEDULE 13G · 2026-05-14
Exhibit 99.2 The identity and the Item 3 classification of the relevant subsidiary is: Bleichroeder LP, which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
Read attachment ↗